Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
Objective: To evaluate the efficacy of deutetrabenazine (DTBZ) in reducing TD in the most severely impacted patients using data from an ongoing open-label extension (OLE)…Long-Term Treatment With Deutetrabenazine (DTBZ) Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From the Completed, 3-year Open-Label Extension (OLE) Study
Objective: To evaluate long-term efficacy and safety of DTBZ in patients with TD by examining change from baseline in Abnormal Involuntary Movement Scale (AIMS) scores…Long-term Safety and Efficacy of Deutetrabenazine in Younger and Older Patients With Tardive Dyskinesia
Objective: To assess the long-term safety and efficacy of deutetrabenazine in younger (<55 years) and older (≥55 years) patients with tardive dyskinesia (TD). Background: TD…Mechanisms of chronic neuroleptic-induced parkinsonism examined with positron emission tomography
Objective: To investigate the cause of chronic neuroleptic drug-induced parkinsonism (NIP) through examination of the profile of striatal monoaminergic nerve terminal density using positron emission…Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study
Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia
Objective: To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD). Background: TD,…Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.